REFERENCES

1. Mery E, Hommel-Fontaine J, Capovilia M, et al. Peritoneal malignant mesothelioma: review and recent data. Ann Pathol 2014;34:26-33.

2. Consonni D, Calvi C, De Matteis S, et al. Peritoneal mesothelioma and asbestos exposure: a population-based case-control study in Lombardy, Italy. Occup Environ Med 2019;76:545-53.

3. Kanarek MS, Liegel JCO. Asbestos intalc and mesothelioma: review of the causality using epidemiology. ESMED 2020:8.

4. Bridda A, Padoan I, Mencarelli R, et al. Peritoneal mesothelioma: a review. MedGenMed 2007;9:32.

5. Carbone M, Adsumolli PA, Alexander HR, et al. Mesothelioma: scientific clues for prevention, diagnosia and therapy. CA Cancer J Clin 2019;69:402-29.

6. Delgermaa V, Takahashi K, Park EK, Le GV, Hara T, Sorahan T. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ 2011;89:716-24.

7. Boffetta P. Epidemiology of peritoneal mesothelioma: a review. Ann Oncol 2007;18:985-90.

8. Oddone E, Bollon J, Nava CR, et al. Forecast of malignant peritoneal mesothelioma mortality in Italy up to 2040. Int J Environ Res Public Health 2020;18:160.

9. Moolgavkar SH, Meza R, Turim J. Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973-2005. Cancer Causes Control 2009;20:935-44.

10. Kusamura S, Kepenekian V, Villeneuve L, et al. Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol 2021;47:36-59.

11. Verwaal VJ, Kusamura S, Baratti D, Deraco M. The eligibility for local-regional treatment of peritoneal surface malignancy. J Surg Oncol 2008;98:220-3.

12. Sugarbaker PH, Chang D. Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. Eur J Surg Oncol 2017;43:1228-35.

13. Cartenni G, Manegold C, Martin Garcia G, et al. Malignant peritoneal mesothelioma-results from the international expanded access program using pemetrexed alone or in combination with a platinum agent. Lung Cancer 2009;64:211-18.

14. Jänne PA, Wozniak AJ, Belani CP, et al. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer 2005;7:40-6.

15. Simon GR, Verschraegen CF, Janne PA, et al. Pemetrexad plus gemcitabine as first line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II tria. J Cin Oncol 2008;26:3567-72.

16. Le DT, Deavers M, Hunt K, Malpica A, Verschraegen CF. Cisplatin and irinotecan (CPT-11) for peritoneal mesothelioma. Cancer Invest 2003;21:682-9.

17. Sgarbura O, Gourgou S, Tosi D, et al. MESOTIP: phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy vs. systemic chemotherapy alone as 1st-line treatment of malignant peritoneal mesothelioma. Pleura Peritoneum 2019;4:20190010.

18. Fennell DA, Ewings S, Ottensmeier C, et al. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol 2021;22:1530-40.

19. Tanaka T, Miyamoto Y, Sakai A, Fujimoto N. Nivolumab for malignant peritoneal mesothelioma. BMJ Case Rep 2020;13:e237721.

20. White MG, Schulte JJ, Xue L, et al. Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy. Br J Cancer 2021;124:564-6.

21. Yonemura Y. Reasons why systemic chemotherapy cannot cure patients with cancer. In: Yonemura, Y, editor. Comprehensive treatment for peritoneal surface malignancy with an intent of cure. Asian School of Peritoneal Surface Oncology: Japanese; 2019. p. 138-139.

22. Dubreuil J, Giammarite F, Rouset P, et al. The role of 18F-FDG-PET/ceCT in peritoneal mesothelioma. Nucl Med Commun 2017;38:312-18.

23. Laterza R, Kusamura S, Baratti D, et al. Role of explorative laparoscopy to evaluate optimal candicates for cytoreductive surgery and hyperthermaic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal mesothelioma. In Vivo 2009;23:187-90.

24. Baratti D, Kusamura S, Deraco M. Circulating CA125 and diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol 2009;35:1198-9.

25. Ramp A, Morikawa Y, Tanaka M, et al. Binding of ovarian cancer antigen CA125/MUC 16 to mesothelin mediated cell adhesion. J Biol Chem 2004;279:9190-8.

26. Kaya H, Sezgı C, Tanrıkulu AC, et al. Prognostic factors influencing survival in 35 patients with malignant peritoneal mesothelioma. Neoplasma 2014;61:433-8.

27. Salo SAS, Ilonen I, Laarksonen S, et al. Malignant peritoneal mesothelioma: treatment options and survival. Anticancer Res 2019;39:839-45.

28. Sugarbaker PH, Welch LS, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am 2003;12:605-21.

29. Baratti D, Kusamura S, Cabras AD, et al. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by nyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer 2013;49:3140-8.

30. Kepenekian V, Elias D, Passot G, et al. Diffuse naliganat peritoneal mesothelioma: evaluation od systemic chemotherapy with comprehensive treatment through the RENAPE database multi-institutional retrospective study. Euro J Cancer 2016;65:69-79.

31. Alexander HR, Bartlet DB, Pingpank JF, et al. Treatment factors associated with lon-term survival after cytoreductive surgery snd regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery 2013;153:779-86.

32. Helm JH, Miura JT, Glenn JA, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol 2015;22:1686-93.

33. Yonemura Y, Ishibashi H, Canbay E, et al. Treatment results of diffuse malignant peritoneal mesothelioma. Gan Kagaku Ryoho 2012;39:2416-9.

34. Magge D, Zenati MS, Austin F, et al. Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Ann Surg Oncol 2014;21:1159-65.

35. Pavlisko EN, Roggli VL. Sarcomatoid peritoneal mesothelioma: clinicopathologic correlation of 13 cases. Am J Surg Pathol 2015;11:1568-75.

36. Naffouje S, Tufla KA, Salti GI. The impact of chemotherapy and its timing on survival in malignanrt peritoneal mesothelioma treated with complete debulking. Med Onco 2018; doi: 10.1007/s12032-018-1125-4.

37. Deraco M, Baratti D, Hutanu I, Bertuli R, Kusamura S. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2013;20:1093-100.

38. Lopock JR. Cellular effects of hyperthermia, relevance to the minimum dose for thermal damage. In J Hyperthermia 2003;19:252-66.

39. Yonemura Y. Treatment of peritoneal metastasis from rare diseases: well-differentiated papillary peritoneal mesothelioma. Asian School of Peritoneal Surface Oncology: Japanese.2019. p.166-7.

40. Le Roy F, Gelli M, Hollebecque A, et al. Conversion to complete cytoreductionsurgery and hyperthermic intraperitoneal chemotherapy fornmaliganat peritoneal mesothelioma after bidirectional chemotherapy. Ann Surg Oncol 2017;24:3640-6.